Slide 1: Dexcom earnings Q4 2024
bpexcom Dexcom earnings OIE aoc Acag ' Q4 2024 Hi Bgiabetes
Slide 2: Safe harbor statement
Safe harbor statement This presentation contains “forward-looking statements” that are based on our management's beliefs and assumptions and on information available to management as of February 13, 2025. We intend for such forward-looking statements to be covered by the safe harbor provisions for f
Slide 3: Fourth quarter 2024
Fourth quarter 2024 idl © Key Financial Strategic $1.114 billion in revenue Highlights Highlights 8% organic revenue! growth over Q4'23. Generated record operating cash Submitted Dexcom G7 15-day CGM (4% US; 19% INT'L2) flow of over $300M system to the FDA for review Secured reimbursement for Dexcom
Slide 4: Fourth quarter performance
Fourth quarter performance Total Revenue & Organic Growth Rate”! Non-GAAP Gross Profit and Margin* (sm™) ($MM) $1,200 , $1,035 $1.14 750 $664 638 $1000 $921 $1,004 $994 be $569 $ $626 $661 $800 $450 $600 $400 $300 $200 +26% +16% +3% +8% $150 64.2% 63.5% 63.0% 59.4% $0 $0 Q4'23 Q124 Q2'24 Q3'24 Q4'24
Slide 5: 2025 Guidance as of February 13, 2025
2025 Guidance as of February 13, 2025 Annual Revenue and Profitability Guidance Revenue USD 4.60 billion Non-GAAP Gross Profit Margin* ~64-65% Non-GAAP. Operating Margin” Adjusted EBITDA is defined as EBITDA adjusted to exclude non-recurring charges and stock-based compensation, * See the appendix f
Slide 6: Appendix: Revenue Data and GAAP Reconciliations
bpexcom Appendix Revenue Data and GAAP Reconciliations
Slide 7: GAAP to non-GAAP reconciliation
Three Months Ended December 31, Three Months Ended December 31, (In millions) 2024 2023 (In millions, except per share data) 2024 2023 GAAP gross profit $ 655.8 $ 656.6 GAAP net income $ 151.7 $ 256.3 Amortization of intangible assets (1) 7.2 7.2 Amortization of intangible assets (1) 8.0 10.1 Busine
Slide 8: Revenue Metrics By Component
Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 FY'22 FY'23 FY'24 Revenue Metrics By Component Sensor & Other Revenue (millions) (1) (2) $ 543.2 $ 597.7 $ 666.6 $ 714.8 $ 651.9 $ 778.0 $ 873.8 $ 947.0 $ 854.3 $ 947.0 $ 951.8 $ 1,068.5 $ 2,522.3 $ 3,250.7 $ 3,821.6 Year over y
Slide 9: Revenue Metrics By Geography
Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 FY'22 FY'23 FY'24 Revenue Metrics By Geography US Revenue (millions) $ 451.2 $ 511.0 $ 573.4 $ 606.4 $ 526.0 $ 616.6 $ 713.6 $ 769.1 $ 653.2 $ 731.9 $ 701.9 $ 802.8 $ 2,142.0 $ 2,625.3 $ 2,889.8 Year over year growth 18% 11% 17%
Slide 10: Organic Revenue reconciliation
Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 FY'22 FY'23 FY'24 (1) Organic Revenue INT'L Revenue - Reported $ 177.6 $ 185.2 $ 196.2 $ 208.8 $ 215.5 $ 254.7 $ 261.4 $ 265.4 $ 267.8 $ 272.4 $ 292.3 $ 310.7 $ 767.8 $ 997.0 $ 1,143.2 Impact of Acquired Revenue (6.4) (9.0) (3.0
Slide 11: Non-GAAP definitions
DexCom, Inc. Amortization of intangible assets - We are required under GAAP to record the fair values of the intangible assets of the entity on our balance sheet and amortize them over their useful lives. We exclude these non-cash amortization charges related to acquired intangible assets from our n